The identification of new genes and molecules able to modulate/inhibit the TOR pathway with a similar or different mechanism as rapamycin can be considered an important goal to enrich the strategy and tools employable in cancer therapy or in pathology related to TOR pathway deregulation. This evidence concerns the gene RORC and cancer.